登录

Boan Bio Closes ¥682M Strategic Financing, Expanding Biological Drug Business Globally

作者: Mailman 2021-01-12 02:15
博安生物
https://www.boan-bio.com
企业数据由 动脉橙 提供支持
综合性生物药品研发制造商 | IPO | 被并购
中国-山东
2022-12-30
融资金额:hk$1.528亿
查看

According to PRNewswire.com, Luye Pharma Group announced that Shandong Boan Biological Technology Co. Ltd. ("Boan Bio"), its subsidiary, has completed a round of strategic financing worth 682 million RMB. The financing is based on the valuation of Boan Bio of 4.85 billion RMB before the capital increase. A number of domestic and international well-known investment firms including YuanBio Venture Capital, Advantech Capital, Qianhai Ark Assets Management, BioVeda China Fund, Blue Ocean Capital and Brill Capital participated in the latest round.


Proceeds from this round will mainly be used to accelerate the development of multiple antibodies and biosimilar drugs of Boan Bio and strengthen its market competitiveness to develop steadily and rapidly. Therefore, the participation of these strategic investors will help Boan Bio to get the leading position in the industry and accelerate its development into "China's leading global bio-pharmaceutical enterprise".


Boan Bio produces and sells wholesales drugs. The company distributes antibiotic drugs, respiratory drugs, cardiovascular drugs, vitamin tablets, health care drugs, and other related products. The company's antibody discovery based on four platforms, namely the phage display platform of fully human antibodies from transgenic mice, antibody-drug conjugate (ADC) technology platform, and platforms for bi-specific T-cell engagers (BiTEs) and nanobodies.


Boan Bio is also actively exploring cutting-edge technologies. Its cell therapy products use non-viral vectors to prepare CAR T-cells for advanced solid tumors. It continues to develop the new generation of generic and regulated CAR-T that are more effective, more affordable, and much safer. In addition to China, Boan is engaged in biological product development in the United States and the European Union.


As one of the main businesses of the group, Boan Bio is accelerating its global biopharmaceutical strategy. With the capability of innovation, the company has developed more than ten antibodies with international intellectual property, and eight biological drugs. Among them, one drug is under the phaseⅠclinical trial in China.


>>>>

About YuanBio Venture Capital


Founded in September 2013, YuanBio Venture Capital manages the new bio-industry funds of 540 million yuan. The company invests in life sciences companies such as biotechnology, drug discovery, medical devices and healthcare services companies in the early stages. It provides capital, management, operation, and other post-investment support and services.


>>>>

About Advantech Capital


Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on the sectors including TMT & E-services and healthcare. Under Mr. Jianming Yu’s leadership, Advantech Capital is managed by over a dozen seasoned investment professionals with a fund size of about US$560 million.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】独家专访“岷山行动”杨寒朔,联合君联资本孵化 “臻愈生物”并完成种子轮融资

实体瘤细胞治疗“黑马”:首个TIL药物获批国内临床

百凯医药创新型抗体偶联药(ADC)BIO-106 IND 申请获得美国 FDA 批准

深耕外泌体产业领域6年,宇玫博生物瞄准罕见病和病毒领域进发

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

MaxiNovel Pharmaceuticals Announces ¥200M Series C Financing

2021-01-12
下一篇

Onechip Bioelectronics Snares ¥10M in Series B from MatrixPartners China

2021-01-12